Dr. Frank D. Cirisano MD

1. Cirisano FD, Greenspoon JS, Stenson R, Farias-Eisner R, Karlan BY, Lagasse LD:  The  etiology and management of diarrhea in the gynecologic oncology patient.  Gynecol Oncol  50:45-48, 1993.

2. Farias-Eisner RF, Cirisano FD, Grouse D, Leuchter R, Karlan BY, Lagasse LD, Berek JS:Conservative and individualized surgery for early squamous carcinoma of the vulva:  The treatment of choice for stages I & II (T1-2 N0-1 M0) disease.  Gynecol Oncol 53:55-58, 1994.

3. Farias-Eisner R, Cirisano FD, Berek JS: ACOG human papilloma virus - computer interaction program.  American College of Obstetrics and Gynecology Teaching Series,(1994).

4. Karlan BY, Baldwin RL, Cirisano FD, Mamula PW, Jones JJ, Lagasse LD: Secreted ovarian epithelial substance inhibits ovarian epithelial cell proliferation. Gynecol Oncol  59:67-74, 1995.

5. Casey AC, Farias-Eisner R, Pisani AL, Cirisano FD, Kim YB, Muderspach L, Futoran R,  Leuchter RS, Lagasse LD, Karlan BY: What is the role of reassessment laparoscopy in the  management of gynecologic cancers in 1995? Gynecol Oncol  60:454-61, 1996.

6. Cirisano FD, Lee S, Greenspoon JS:  Apparent heparin resistance due to elevated factor VIII in a patient with post-operative deep venous thrombosis:  Case Report. J Repro Med  41;3:191-194, 1996.

7. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD: Cell Cycle Control of BRCA2.  Cancer Research 56:4590-4594, 1996.

8. Berchuck A, Cirisano FD, Lancaster J, Schildkraut JM, Wiseman RW, Futreal A, Marks JR:   Role of BRCA1 mutation screening in the management of familial ovarian cancer.  Am J  Obstet Gynecol 175:738-746, 1996.

9. Elbendary A, Cirisano FD, Evans AC, Jr.,  Davis PL, Iglehart JD, Marks JR, Berchuck A:   Relationship between p21 expression and mutation of the p53 tumor suppressor gene in  normal and malignant ovarian epithelial cells. Clin Cancer Res  2:1571-1575, 1996.

10. Ng WL, Schummer M, Cirisano FD, Baldwin RL, Karlan BY, Hood LE: High-throughput plasmid mini preparations facilitated by micro-mixing. Nucleic Acids Res 24(24):5045-5047, 1996.

11. Clifford SL, Kaminetsky CP, Cirisano FD, Dodge R, Soper JT, Clarke-Pearson DL, Berchuck A:  Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer.  Am J Obstet Gynecol 176 (6):S229-S232, 1997.

12. Eachempati SR, Young C, Alexander J, Cirisano FD, Rodriguez GC, Reed II, RL: The use of esophageal doppler monitoring in a patient with early intracardiac Greenfield filter migration. J Vasc Surg (In Press).

13. Cirisano FD, Soper JT. Clinical management of gestational trophoblastic disease. Primary Care Ob/Gyn. March 1998; 4: 4-8.

14. Ng WL, Schummer M, Bumgarner RE, Cirisano, FD, Baldwin RL, Karlan BY and Hood L. High-density cDNA array expression mapping of human ovarian tumors. Proc Amer Assoc Cancer Res 1996; 37: 517.

15. Cirisano FD. Management of Preinvasive disease of the cervix. Seminars in Surgical Oncology. 1999; In Press.

16. Gilliam LK, Scearce RM, Cirisano FD, Lobenhofer E, Marks JR, Hale LP. Production of a monoclonal antibody reactive with BRCA2 protein sequences. Proceedings of the American Association for Cancer Research 1997; 38: 243.

17. Cirisano FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL. Epidemiologic and surgico-pathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999; 74: 385-393.

18. Cirisano FD, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers compared with endometrioid carcinoma.  Gynecol Oncol 1999 (in press).